ArticleCell death & disease2026
BMSC-derived extracellular vesicles enhance osteosarcoma proliferation and metastasis via the circRNA-0010220/β-catenin pathway.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Osteosarcoma (OS) remains a challenging malignancy with a high propensity for metastasis and poor survival outcomes. Bone marrow mesenchymal stem cell-derived extracellular vesicles (BMSC-EVs) have emerged as key mediators in the tumor microenvironment, promoting OS progression. This study identifies a novel molecular axis centered on circRNA-0010220 within BMSC-EVs that drives OS aggressiveness. We demonstrate that BMSC-EVs are internalized by OS cells, enhancing their proliferation, migration, and invasion. High-throughput sequencing revealed circRNA-0010220 as the most significantly upregulated circRNA in EV-treated OS cells. Functional studies showed that circRNA-0010220 knockdown in BMSCs attenuated the oncogenic effects of their EVs both in vitro and in vivo. Mechanistically, circRNA-0010220 recruits the histone methyltransferase EZH2 to the CTNNBIP1 promoter, facilitating H3K27me3-mediated epigenetic silencing. The subsequent downregulation of CTNNBIP1 leads to activation of the Wnt/β-catenin signaling pathway. This cascade was consistently observed across gain-of-function and loss-of-function experiments, and pharmacologic inhibition of β-catenin reversed the pro-tumorigenic effects. Our findings elucidate a complete signaling axis from BMSC-EVs to Wnt/β-catenin activation via circRNA-0010220/EZH2/CTNNBIP1, providing new insights into the epigenetic regulation of OS progression and suggesting potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.